RNS Number : 2758U MaxCyte, Inc. 01 December 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 1 December 2021 : MaxCyte (LSE: MXCT, MXCN), a leading commercial cell - engineering company focused on providing enabling platform technologies to
RNS Number : 2493T MaxCyte, Inc. 23 November 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Purchase of Common Stock - PDMR dealing Gaithersburg, Maryland , November 23, 2021 - M axCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused
RNS Number : 7413S MaxCyte, Inc. 17 November 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options, PDMR dealing and Total Voting Rights Gaithersburg, Maryland , November 17, 2021 - M axCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial
RNS Number : 0207S MaxCyte, Inc. 11 November 2021 MaxCyte Reports Third Quarter Financial Results GAITHERSBURG, MD , November 11, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to
RNS Number : 2161R MaxCyte, Inc. 03 November 2021 MaxCyte Board Member Richard Douglas , PhD, Appointed Independent Chairman of the Board GAITHERSBURG, MD , Nov. 3, 2021 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT, MXCN) is a leading commercial cell-engineering company focused on
RNS Number : 7940Q MaxCyte, Inc. 29 October 2021 Result of AGM GAITHERSBURG, MD , October 29, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research
RNS Number : 6206Q MaxCyte, Inc. 28 October 2021 MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs Nkarta to use MaxCyte's Flow Electroporation ® technology and ExPERT ™ platform to accelerate the development of its oncology
RNS Number : 2022Q MaxCyte, Inc. 26 October 2021 MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021 GAITHERSBURG, MD , October 26, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling
RNS Number : 1277O MaxCyte, Inc. 06 October 2021 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN US57777K1060 Issuer Name MAXCYTE, INC. UK or Non- UK Issuer Non- UK 2. Reason for Notification An acquisition or disposal of voting rights; An acquisition or
RNS Number : 8000N MaxCyte, Inc. 01 October 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Notice of Annual General Meeting Change of Director Gaithersburg, Maryland - 1 October 2021 : MaxCyte, Inc ( NASDAQ: MXCT; LSE: MXCT, MXCN ), a leading commercial cell - engineering company
